VSA006

VSA006 is a small interfering RNA (siRNA) drug from Visirna Therapeutics, a Greater-China joint venture that Arrowhead Pharmaceuticals and Vivo Capital formed in April 2022 to develop Arrowhead's RNAi assets in mainland China, Hong Kong, Macau, and Taiwan [3]. It is designed to silence HSD17B13 in liver cells for the treatment of MASH (metabolic dysfunction-associated steatohepatitis, the disease renamed from NASH by international consensus in 2023). VSA006 is currently in a small Phase 2 trial in Chinese MASH patients (NCT06322628, n=48) [1]. The target is one of the most genetically validated in all of liver disease: humans who carry a loss-of-function version of HSD17B13 have roughly 30 to 50 percent lower risk of cirrhosis and liver cancer, which is why both Arrowhead (now via GSK, as GSK4532990) and Regeneron (via ALN-HSD, in-licensed from Alnylam) have built silencing programs against it [2, 6].

VSA006 is a novel investigational compound, never approved anywhere. It is a subcutaneously dosed GalNAc-conjugated siRNA, meaning it is a short strand of RNA chemically hitched to a sugar tag (N-acetylgalactosamine) that latches onto a receptor on liver cells and drags the drug specifically into hepatocytes. That delivery chemistry is common to both Arrowhead's TRiM platform and Alnylam's ESC platform, and is consistent with Visirna's origin as a Greater China JV that Arrowhead and Vivo Capital launched in April 2022 with $60 million in seed funding [3]. Arrowhead granted Visirna exclusive Greater-China rights to four RNAi therapeutics for cardiometabolic disease, and since Arrowhead retained Greater-China rights when out-licensing ARO-HSD to GSK, VSA006 is likely the Greater-China arm of that same HSD17B13 program (Visirna has not publicly confirmed this). The Phase 2 trial (NCT06322628) is a multicenter, randomized, double-blind, placebo-controlled study that started dosing on April 22, 2024, with a planned enrollment of 48 and an estimated primary completion date of July 2026 [1]. No FDA designations apply because the trial is running under China's NMPA (National Medical Products Administration); a US IND (Investigational New Drug application) has not been publicly disclosed. Visirna has not publicly disclosed Phase 1 data for VSA006, making it difficult to assess target engagement magnitude or safety profile ahead of the Phase 2 readout.

HSD17B13 is a protein that sits on lipid droplets, the fat-storage bubbles inside liver cells, and helps process fatty molecules and retinol (vitamin A) [4]. In people whose livers are chronically inflamed by fat, alcohol, or viral hepatitis, HSD17B13 activity appears to worsen the injury. The proposed biological mechanism is not fully nailed down, but current evidence points to HSD17B13 generating retinoic acid and lipid-derived metabolites (including candidate 11-keto-prostaglandin species) that may dysregulate retinol signaling and amplify hepatic stellate cell activation, the pathway that drives fibrosis. That mechanism-of-harm story remains incompletely characterized, which is why the strong genetic evidence alone does not guarantee that pharmacological silencing will reverse established disease. The genetic evidence itself is unusually clean: a common variant (rs72613567) that knocks out the protein was linked in a large exome study to major protection against alcoholic and non-alcoholic liver disease, cirrhosis, and hepatocellular carcinoma [2]. That is a natural human experiment showing what a drug that silences HSD17B13 might do. VSA006 is an siRNA, which works by feeding the cell a decoy piece of RNA that base-pairs with the HSD17B13 messenger RNA and triggers its destruction, so the protein is never made. Because the GalNAc tag routes the drug almost exclusively to hepatocytes, off-target silencing in other tissues is limited. The strength of the case is real but not fully proven: no HSD17B13 silencer has yet posted a positive histology readout, so the leap from genetic protection to reversal of established fibrosis in patients who already have advanced disease remains a hypothesis.

NCT06322628 is a Phase 2 study in Chinese MASH patients (NASH was renamed MASH by international consensus in 2023, same disease) with a planned enrollment of 48 [1]. It is multicenter, randomized, double-blind, and placebo-controlled. The primary endpoint is the percentage of participants achieving at least one stage improvement in liver fibrosis on biopsy with no worsening of MASH activity, which is a standard MASH histology endpoint aligned with what Madrigal used for resmetirom. Fibrosis is scored on the F0 to F4 scale (F0 = no fibrosis, F1 = mild, F2 = significant, F3 = advanced/bridging, F4 = cirrhosis). Comparator arm and dosing regimen details are not fully disclosed in the public registry entry. The trial started dosing on April 22, 2024, with an estimated primary completion date of July 2026 and overall completion in January 2027 [1]. Design concerns: 48 patients is small for a fibrosis endpoint where placebo response can run 15 to 25 percent, so this trial is powered to detect a large effect, not a subtle one. It is also single-country, which limits generalizability to Western MASH populations that dominate the commercial market. Visirna has not publicly disclosed Phase 1 data for VSA006, so target-knockdown magnitude and any early safety signals are not visible to outside analysts. On the positive side, biopsy-confirmed histology is the harder endpoint regulators respect, not a surrogate like liver fat measured by MRI (specifically MRI-PDFF, magnetic resonance imaging proton density fat fraction). A clear histology signal here would carry weight for the broader HSD17B13 thesis even at n=48.

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 23%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest concern. Silencing HSD17B13 could lower an enzyme that people who inherited the LOF variant have been without their whole lives, and still not reverse established fibrosis in patients who already have advanced disease. Neither of the two more advanced HSD17B13 programs has yet posted a Phase 2 histology readout, which is the actual class signal to watch. Arrowhead's ARO-HSD showed roughly 84 percent HSD17B13 mRNA knockdown in Phase 1/2 and was out-licensed to GSK in November 2021 for $120 million upfront plus up to $910 million in milestones; GSK renamed it GSK4532990 and dosed the first Phase 2b patient in March 2023, triggering a $30 million milestone to Arrowhead [6]. Alnylam and Regeneron reported encouraging ALN-HSD Phase 1 data in September 2022 (robust knockdown, numerically lower liver enzymes and NAFLD activity score over six months versus placebo); Alnylam then opted out of further development in late 2022 and Regeneron has led the program from Phase 2 onward [7]. Two active Western-patient programs with no histology readout yet is uncertainty about the class, not evidence of failure. Commercial risk is substantial. Madrigal's resmetirom (Rezdiffra) was approved in March 2024 as the first drug for MASH with F2 to F3 fibrosis and posted $180.1 million in 2024 full-year revenue with a steep launch curve into 2025 [8]. GLP-1 receptor agonists, particularly semaglutide and tirzepatide, are also moving into MASH with strong weight-loss driven histology data. Any HSD17B13 silencer arriving in 2028 or later will need to show either a differentiated safety profile, additive benefit on top of GLP-1s, or efficacy in patients who cannot tolerate them. Safety risk appears low based on the LOF-variant human data, but subcutaneous siRNAs occasionally show injection-site reactions and transient rises in liver function tests (LFTs, blood markers of liver-cell damage). Execution risk in a 48-patient single-country trial run by a small private JV is nontrivial.

Watch, but do not overweight. VSA006 matters less for its own commercial potential in China than as one of three shots on goal for the HSD17B13 hypothesis, alongside GSK4532990 (Phase 2b, most advanced) and Regeneron's ALN-HSD. The signal to look for is a histology readout, not liver fat or ALT reduction, from any HSD17B13 program in the next 18 to 24 months. That is the data point that would either validate the mechanism for the entire field or effectively close it. GSK4532990 is the most advanced Western-patient program, so its Phase 2b readout is the single biggest catalyst for the class [6]. Visirna itself is worth tracking as a case study in Arrowhead's China strategy: the JV was seeded with $60 million from Vivo Capital in April 2022 and granted exclusive Greater-China rights to four Arrowhead RNAi cardiometabolic assets [3]. Because Arrowhead retained Greater-China rights when out-licensing ARO-HSD to GSK, VSA006 is likely the Greater-China arm of that same program, though Visirna has not publicly confirmed the identity. Check back after any GSK4532990 or ALN-HSD Phase 2 disclosure, or if Visirna files a US IND. The MASH market is being reshaped by resmetirom and GLP-1s in real time, so the bar for a fourth mechanism keeps rising.